| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 983 | 2018 |
| Identifying prodromal Parkinson's disease: pre‐motor disorders in Parkinson's disease RB Postuma, D Aarsland, P Barone, DJ Burn, CH Hawkes, W Oertel, ... Movement Disorders 27 (5), 617-626, 2012 | 779 | 2012 |
| Stroke-induced immunodepression: experimental evidence and clinical relevance U Dirnagl, J Klehmet, JS Braun, H Harms, C Meisel, T Ziemssen, K Prass, ... Stroke 38 (2), 770-773, 2007 | 664 | 2007 |
| Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ... Jama 321 (2), 175-187, 2019 | 483 | 2019 |
| Glatiramer acetate‐specific T‐helper 1‐and 2‐type cell lines produce BDNF: implications for multiple sclerosis therapy T Ziemssen, T KuÈmpfel, WEF Klinkert, O Neuhaus, R Hohlfeld Brain 125 (11), 2381-2391, 2002 | 369 | 2002 |
| Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid C Schläger, H Körner, M Krueger, S Vidoli, M Haberl, D Mielke, E Brylla, ... Nature 530 (7590), 349-353, 2016 | 359 | 2016 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 332 | 2018 |
| Non-motor dysfunction in Parkinson's disease T Ziemssen, H Reichmann Parkinsonism & related disorders 13 (6), 323-332, 2007 | 317 | 2007 |
| Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study A Rolfs, F Fazekas, U Grittner, M Dichgans, P Martus, M Holzhausen, ... Stroke 44 (2), 340-349, 2013 | 293 | 2013 |
| Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study K Selmaj, DKB Li, HP Hartung, B Hemmer, L Kappos, MS Freedman, ... The Lancet Neurology 12 (8), 756-767, 2013 | 283 | 2013 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 276 | 2017 |
| Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, L Vanopdenbosch, ... The Lancet Neurology 16 (3), 189-199, 2017 | 264 | 2017 |
| The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis N Kawakami, S Lassmann, Z Li, F Odoardi, T Ritter, T Ziemssen, ... The Journal of experimental medicine 199 (2), 185-197, 2004 | 252 | 2004 |
| Multiple sclerosis beyond EDSS: depression and fatigue T Ziemssen Journal of the neurological sciences 277, S37-S41, 2009 | 236 | 2009 |
| Optimizing treatment success in multiple sclerosis T Ziemssen, T Derfuss, N de Stefano, G Giovannoni, F Palavra, D Tomic, ... Journal of neurology 263, 1053-1065, 2016 | 233 | 2016 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 231 | 2017 |
| Molecular biomarkers in multiple sclerosis T Ziemssen, K Akgün, W Brück Journal of neuroinflammation 16 (1), 272, 2019 | 228 | 2019 |
| Psychoneuroimmunology–cross-talk between the immune and nervous systems T Ziemssen, S Kern Journal of neurology 254, II8-II11, 2007 | 215 | 2007 |
| Cardiovascular autonomic dysfunction in Parkinson's disease T Ziemssen, H Reichmann Journal of the neurological sciences 289 (1-2), 74-80, 2010 | 213 | 2010 |
| Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors I Krause, S Kern, A Horntrich, T Ziemssen Multiple Sclerosis Journal 19 (13), 1792-1799, 2013 | 205 | 2013 |
Rocco HaaseCenter of Clinical Neuroscience在 uniklinikum-dresden.de 的电子邮件经过验证
